|
1) Fenstermacher N, Levin M, Ward T. Pharmacological prevention of migraine. BMJ. 2011; 342: d583
|
|
|
|
2) Shimizu T, Shibata M, Suzuki N. [Migraine: advances in the pathophysiology and treatment]. Rinsho Shinkeigaku. 2011; 51: 103-9
|
|
|
|
|
3) Domingues RB, Silva AL, Domingues SA, et al. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the com-bination of propranolol and nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr. 2009; 67: 973-7
|
|
|
|
|
|
4) Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001; 133: 1330-8
|
|
|
|
|
|
5) Schellenberg R, Lichtenthal A, Wohling H, et al. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment？ Headache. 2008; 48: 118-25
|
|
|
|
|
|
6) Holroyd KA, Cottrell CK, OʼDonnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. 2010; 341: c4871
|
|
|
|
|
|
7) Schrader H, Stovner LJ, Helde G, et al. Pro-phylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001; 322: 19-22
|
|
|
|
|
|
8) Tronvik E, Stovner LJ, Helde G, et al. Prophy-lactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003; 289: 65-9
|
|
|
|
|
|
9) Schuh-Hofer S, Flach U, Meisel A, et al. Efficacy of lisinopril in migraine prophylaxis--an open label study. Eur J Neurol. 2007; 14: 701-3
|
|
|
|
|
|
10) Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily head-ache. Headache. 2011; 51: 33-51
|
|
|
|
|
|
11) Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004; 61: 490-5
|
|
|
|
|
|
12) Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008; 118: 301-5
|
|
|
|
|
|
13) Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009; 31: 542-59
|
|
|
|
|
|
14) Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transfor-mation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011; 31: 18-30
|
|
|
|
|
|
15) Lampl C, Katsarava Z, Diener HC, et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005; 76: 1730-2
|
|
|
|
|
|
16) Bermejo PE, Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol. 2009; 32: 103-6
|
|
|
|
|
|
17) Villani V, Ciuffoli A, Prosperini L, et al. Zonis-amide for migraine prophylaxis in topiramate-intolerant patients: an observational study. Headache. 2011; 51: 287-91
|
|
|
|
|
|
18) Slater SK, Nelson TD, Kabbouche M, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011; 31: 897-905
|
|
|
|
|
|
19) Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804-14
|
|
|
|
|